Drugs / QLS1103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05884801 | Jun 2023 → Jan 2025 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Qilu Pharmaceutical Co., Ltd. | Results 凤凰网丨齐鲁制药两款抗肿瘤创新药最新临床数据亮相ESMO亚洲年会 qilu-pharma.com ↗
安全性方面，未发生剂量限制性毒性（DLT），最大耐受剂量（MTD）未达到，共计5例受试者发生≥3级治疗相关不良事件（TRAE）。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-15 | Qilu Pharmaceutical Co., Ltd. | 凤凰网丨齐鲁制药两款抗肿瘤创新药最新临床数据亮相ESMO亚洲年会 qilu-pharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS1103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05884801 ↗ |
| Route | Oral | “Oral dose” NCT05884801 ↗ |